Physician profile
Irving D Wolfe
NPI 1508832346
$580.11
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $57.61 · 2021: $84.01 · 2022: $29.91 · 2023: $16.25 · 2024: $56.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $126.94 | 2019-2021 | |
| Celgene Corporation | $60.75 | 2019 | |
| Pfizer INC. | $48.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $39.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.31 | 2019-2020 | |
| Abbvie INC. | $36.81 | 2019-2022 | |
| Lilly USA, LLC | $35.55 | 2019-2023 | Emgality, Reyvow |
| Merck Sharp & Dohme LLC | $29.86 | 2019 | |
| Janssen Biotech, INC. | $24.91 | 2024 | Simponi, Simponi Aria, Tremfya |
| Vyne Pharmaceuticals INC. | $23.28 | 2020 | |
| Amgen INC. | $21.61 | 2021 | |
| Leo Pharma INC. | $17.89 | 2019 | |
| Arcutis Biotherapeutics, INC. | $15.89 | 2024 | Zoryve |
| Sanofi-Aventis U.S. LLC | $15.76 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.60 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $15.26 | 2019 | |
| Dermavant Sciences, INC. | $15.22 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irving Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.